Home >> Professional Blog

Retrospective Analysis Finds MiMedx EpiFix® As Most Effective In Rapid Resolution Of Diabetic Foot Ulcers When Compared With Two Other Skin Substitutes

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced for investors today that a peer-reviewed study, "An Evaluation of Healing Metrics Associated with Commonly Used Advanced Wound Care products for the Treatment of Chronic Diabetic Foot Ulcers," was electronically published in the July 2014 edition of Managed Care.

The retrospective evaluation examined data for three commonly available skin substitutes: Apligraf®, Dermagraft®, and EpiFix®. Data examined included rates of complete wound closure, time to healing, number of graft applications to wound closure, durability of healed wounds , and safety data. Data for Apligraf® and Dermagraft® included peer-reviewed publications of pivotal clinical study data and physician product prescribing information, as well as other pre-market approval summary documents from the U.S. Food and Drug Administration. The EpiFix® data was from randomized controlled trials of EpiFix®.

The retrospective evaluation concluded: "Although prospective comparative effective trials are needed, the differences recorded suggest EpiFix® results in the most rapid improvement and resolution of diabetic foot ulcers."

The electronic publication can be found at: http://www.managedcaremag.com/archives/2014/7/evaluation-healing-metrics-associated-commonly-used-advanced-wound-care-products.

The summary comments in this press release should be read with reference to the full abstract of the study, which includes the purpose, design, methodology, results and limitations on the study analysis.

Apligraf® and Dermagraft® are registered trademarks of their respective owners.